<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-TTLDQECV</identifier><date>2024</date><creator>Perišić, Milica</creator><relation>documents/doc/T/URN_NBN_SI_doc-TTLDQECV_001.pdf</relation><relation>documents/doc/T/URN_NBN_SI_doc-TTLDQECV_001.txt</relation><format format_type="issue">1</format><format format_type="volume">75</format><format format_type="type">article</format><format format_type="extent">str. 26-33</format><identifier identifier_type="COBISSID_HOST">197436163</identifier><identifier identifier_type="ISSN">2536-4316</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-TTLDQECV</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">Antigeni</subject><subject language_type_id="eng">cancer immunotherapy</subject><subject language_type_id="slv">Cepiva proti raku</subject><subject language_type_id="slv">Imunoterapija</subject><subject language_type_id="slv">imunoterapija raka</subject><subject language_type_id="slv">Klinične raziskave</subject><subject language_type_id="eng">tumor associated antigens</subject><subject language_type_id="slv">tumorji, povezani z antigeni</subject><title>Cepiva za preprečevanje razvoja in zdravljenje rakavih bolezni</title><title>razvojne platforme in trenutni napredek</title><title>Prophylactic and therapeutic cancer vaccines</title><title>development platforms and current progress</title></Record>